TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs
More than 500,000 individuals worldwide living with multiple sclerosis (MS) have been treated with TECFIDERA, which has a well-established safety and efficacy profile
Biogen’s expansion in China now includes treatment options approved for relapsing MS and spinal muscular atrophy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.